Alberto Signore

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1880043/publications.pdf

Version: 2024-02-01

300	10,500	38742	48315
papers	citations	50 h-index	88 g-index

337	337	337	8850
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Imaging techniques for assessment of inflammatory bowel disease: Joint ECCO and ESGAR evidence-based consensus guidelines. Journal of Crohn's and Colitis, 2013, 7, 556-585.	1.3	541
2	EANM/SNMMI Guideline for¹⁸F-FDG Use in Inflammation and Infection. Journal of Nuclear Medicine, 2013, 54, 647-658.	5.0	496
3	FDG-PET/CT(A) imaging in large vessel vasculitis and polymyalgia rheumatica: joint procedural recommendation of the EANM, SNMMI, and the PET Interest Group (PIG), and endorsed by the ASNC. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 1250-1269.	6.4	332
4	NOD mouse colonies around the world- recent facts and figures. Trends in Immunology, 1993, 14, 193-196.	7.5	316
5	Guidelines for the labelling of leucocytes with 99mTc-HMPAO. European Journal of Nuclear Medicine and Molecular Imaging, 2010, 37, 842-848.	6.4	246
6	Added Value of ^{99m}Tc-HMPAOâ€“Labeled Leukocyte SPECT/CT in the Characterization and Management of Patients with Infectious Endocarditis. Journal of Nuclear Medicine, 2012, 53, 1235-1243.	5.0	200
7	The Use of<mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="M1"><mml:mrow><mml:mrow><mml:mn mathvariant="bold">18</mml:mn></mml:mrow></mml:mrow></mml:math>F-FDG-PET/CT for Diagnosis and Treatment Monitoring of Inflammatory and Infectious Diseases. Clinical and Developmental Immunology, 2013, 2013, 1-14.	3.3	198
8	Early prediction of endocrine therapy effect in advanced breast cancer patients using 99mTc-depreotide scintigraphy. Journal of Nuclear Medicine, 2006, 47, 6-13.	5.0	181
9	Guidelines for the labelling of leucocytes with 111In-oxine. European Journal of Nuclear Medicine and Molecular Imaging, 2010, 37, 835-841.	6.4	171
10	Relevance of immune cell and tumor microenvironment imaging in the new era of immunotherapy. Journal of Experimental and Clinical Cancer Research, 2020, 39, 89.	8.6	157
11	Nuclear medicine imaging of bone infections. Nuclear Medicine Communications, 2006, 27, 633-644.	1.1	151
12	Identification and Characterization of a Ligand-independent Oligomerization Domain in the Extracellular Region of the CD95 Death Receptor. Journal of Biological Chemistry, 1999, 274, 38241-38250.	3.4	148
13	The natural history of lymphocyte subsets infiltrating the pancreas of NOD mice. Diabetologia, 1989, 32, 282-289.	6.3	138
14	Consensus document for the diagnosis of prosthetic joint infections: a joint paper by the EANM, EBJIS, and ESR (with ESCMID endorsement). European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 971-988.	6.4	136
15	Clinical indications, image acquisition and data interpretation for white blood cells and anti-granulocyte monoclonal antibody scintigraphy: an EANM procedural guideline. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 1816-1831.	6.4	128
16	Imaging of leukocytic infiltration in human cerebral infarcts.. Stroke, 1985, 16, 251-255.	2.0	120
17	Molecular Imaging of Inflammation/Infection: Nuclear Medicine and Optical Imaging Agents and Methods. Chemical Reviews, 2010, 110, 3112-3145.	47.7	116
18	The molecular imaging approach to image infections and inflammation by nuclear medicine techniques. Annals of Nuclear Medicine, 2011, 25, 681-700.	2.2	110

#	Article	IF	Citations
19	Peptide receptor therapies in neuroendocrine tumors. Journal of Endocrinological Investigation, 2009, 32, 360-369.	3.3	104
20	Recommendations on nuclear and multimodality imaging in IE and CIED infections. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 1795-1815.	6.4	103
21	A large retrospective single-centre study to define the best image acquisition protocols and interpretation criteria for white blood cell scintigraphy with 99mTc-HMPAO-labelled leucocytes in musculoskeletal infections. European Journal of Nuclear Medicine and Molecular Imaging, 2013, 40, 1760-1769.	6.4	97
22	Low-activity (2.0â€ŠGBq; 54â€ŠmCi) radioiodine post-surgical remnant ablation in thyroid cancer: comparison between hormone withdrawal and use of rhTSH in low-risk patients. European Journal of Endocrinology, 2009, 160, 431-436.	3.7	94
23	FDG-PET/CT in infections: the imaging method of choice?. European Journal of Nuclear Medicine and Molecular Imaging, 2010, 37, 1986-1991.	6.4	94
24	Value of the first serum thyroglobulin level after total thyroidectomy for the diagnosis of metastases from differentiated thyroid carcinoma. European Journal of Nuclear Medicine and Molecular Imaging, 1999, 26, 1448-1452.	6.4	92
25	Detection of Osteomyelitis in the Diabetic Foot by Imaging Techniques: A Systematic Review and Meta-analysis Comparing MRI, White Blood Cell Scintigraphy, and FDG-PET. Diabetes Care, 2017, 40, 1111-1120.	8.6	92
26	N-(4-¹⁸F-Fluorobenzoyl)Interleukin-2 for PET of Human-Activated T Lymphocytes. Journal of Nuclear Medicine, 2012, 53, 679-686.	5.0	88
27	Nuclear medicine imaging of diabetic foot infection: results of meta-analysis. Nuclear Medicine Communications, 2006, 27, 757-764.	1.1	85
28	Lessons from the NOD mouse for the pathogenesis and immunotherapy of human Type 1 (insulin-dependent) diabetes mellitus. Diabetologia, 1989, 32, 703-708.	6.3	83
29	Characterization of a New Form of Inherited Hypercholesterolemia. Arteriosclerosis, Thrombosis, and Vascular Biology, 1999, 19, 802-809.	2.4	83
30	Successful treatment with intraarticular infliximab for resistant knee monarthritis in a patient with spondylarthropathy: A role for scintigraphy with99mTc-infliximab. Arthritis and Rheumatism, 2005, 52, 1224-1226.	6.7	82
31	Image acquisition and interpretation criteria for 99mTc-HMPAO-labelled white blood cell scintigraphy: results of a multicentre study. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 615-623.	6.4	82
32	Leukocyte and bacteria imaging in prosthetic joint infection. , 2013, 25, 61-77.		81
33	99mTc-interleukin-2 scintigraphy for the in vivo imaging of vulnerable atherosclerotic plaques. European Journal of Nuclear Medicine and Molecular Imaging, 2006, 33, 117-126.	6.4	78
34	Can Sequential ¹⁸F-FDG PET/CT Replace WBC Imaging in the Diabetic Foot?. Journal of Nuclear Medicine, 2011, 52, 1012-1019.	5.0	78
35	PET/MRI in infectious and inflammatory diseases: will it be a useful improvement?. European Journal of Nuclear Medicine and Molecular Imaging, 2012, 39, 745-749.	6.4	78
36	Radiopharmaceuticals for the study of 4 inflammatory processes. Nuclear Medicine Communications, 1997, 18, 437-458.	1.1	76

#	Article	IF	Citations
37	A joint procedural position statement on imaging in cardiac sarcoidosis: from the Cardiovascular and Inflammation & Infection Committees of the European Association of Nuclear Medicine, the European Association of Cardiovascular Imaging, and the American Society of Nuclear Cardiology. European Heart Journal Cardiovascular Imaging, 2017, 18, 1073-1089.	1.2	74
38	Consensus document for the diagnosis of peripheral bone infection in adults: a joint paper by the EANM, EBJIS, and ESR (with ESCMID endorsement). European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 957-970.	6.4	74
39	Preparation and biodistribution of 99mtechnetium labelled oxidized LDL in man. Atherosclerosis, 1996, 126, 131-141.	0.8	71
40	State of the art of 18F-FDG PET/CT application in inflammation and infection: a guide for image acquisition and interpretation. Clinical and Translational Imaging, 2021, 9, 299-339.	2.1	70
41	Double blind trial of nicotinamide in recent-onset IDDM (the IMDIAB III study). Diabetologia, 1995, 38, 848-852.	6.3	68
42	Diagnostic flowcharts in osteomyelitis, spondylodiscitis and prosthetic joint infection. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2014, 58, 2-19.	0.7	63
43	123I-interleukin-2 scintigraphy for in vivo assessment of intestinal mononuclear cell infiltration in Crohn's disease. Journal of Nuclear Medicine, 2000, 41, 242-9.	5.0	62
44	CT60 Single Nucleotide Polymorphisms of the Cytotoxic T-Lymphocyteâ€“Associated Antigen-4 Gene Region is Associated with Graves' Disease in an Italian Population. Thyroid, 2005, 15, 232-238.	4.5	59
45	A radiopharmaceutical for imaging areas of lymphocytic infiltration: 123I-interleukin-2. Labelling procedure and animal studies. Nuclear Medicine Communications, 1992, 13, 713-722.	1.1	58
46	Imaging bacteria with radiolabelled quinolones, cephalosporins and siderophores for imaging infection: a systematic review. Clinical and Translational Imaging, 2016, 4, 229-252.	2.1	58
47	Role of Combined [68Ga]Ga-DOTA-SST Analogues and [18F]FDG PET/CT in the Management of GEP-NENs: A Systematic Review. Journal of Clinical Medicine, 2019, 8, 1032.	2.4	58
48	The development of technetium-99m-labelled interleukin-2: A new radiopharmaceutical for the In vivo detection of mononuclear cell infiltrates in immune-mediated diseases. Nuclear Medicine and Biology, 1997, 24, 579-586.	0.6	53
49	Peptide radiopharmaceuticals for diagnosis and therapy. European Journal of Nuclear Medicine and Molecular Imaging, 2001, 28, 1555-1565.	6.4	53
50	Consensus document on controversial issues in the diagnosis and treatment of prosthetic joint infections. International Journal of Infectious Diseases, 2010, 14, S67-S77.	3.3	53
51	New frontiers of MRI in Crohnâ€™s disease: motility imaging, diffusion-weighted imaging, perfusion MRI, MR spectroscopy, molecular imaging, and hybrid imaging (PET/MRI). Abdominal Imaging, 2012, 37, 974-982.	2.0	53
52	Joint EANM/ESNR and ESCMID-endorsed consensus document for the diagnosis of spine infection (spondylodiscitis) in adults. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 2464-2487.	6.4	53
53	Can iodine-131 whole-body scan be replaced by thyroglobulin measurement in the post-surgical follow-up of differentiated thyroid carcinoma?. Journal of Nuclear Medicine, 1990, 31, 1766-71.	5.0	53
54	99mTc-labeled Rituximab for Imaging B Lymphocyte Infiltration in Inflammatory Autoimmune Disease Patients. Molecular Imaging and Biology, 2012, 14, 637-646.	2.6	52

#	Article	IF	Citations
55	PET/MR in invasive ductal breast cancer: correlation between imaging markers and histological phenotype. British Journal of Cancer, 2017, 116, 893-902.	6.4	52
56	Staging performance of whole-body DWI, PET/CT and PET/MRI in invasive ductal carcinoma of the breast. International Journal of Oncology, 2017, 51, 281-288.	3.3	52
57	DETECTION OF ACTIVATED LYMPHOCYTES IN ENDOCRINE PANCREAS OF BB/W RATS BY INJECTION OF 123I-INTERLEUKIN-2: AN EARLY SIGN OF TYPE 1 DIABETES. Lancet, The, 1987, 330, 537-540.	13.7	51
58	Imaging active lymphocytic infiltration in coeliac disease with iodine-123-interleukin-2 and the response to diet. European Journal of Nuclear Medicine and Molecular Imaging, 2000, 27, 18-24.	2.1	51
59	A consensus protocol for white blood cells labelling with technetium-99m hexamethylpropylene amine oxime. European Journal of Nuclear Medicine and Molecular Imaging, 1998, 25, 797-799.	6.4	50
60	Nuclear medicine imaging of inflammatory/infective disorders of the abdomen. Nuclear Medicine Communications, 2005, 26, 657-664.	1.1	50
61	Molecular imaging of rheumatoid arthritis by radiolabelled monoclonal antibodies: new imaging strategies to guide molecular therapies. European Journal of Nuclear Medicine and Molecular Imaging, 2010, 37, 386-398.	6.4	50
62	Vitamin E and nicotinamide have similar effects in maintaining residual beta cell function in recent onset insulin-dependent diabetes (the IMDIAB IV study). European Journal of Endocrinology, 1997, 137, 234-239.	3.7	49
63	Non-invasive visualization of tumor infiltrating lymphocytes in patients with metastatic melanoma undergoing immune checkpoint inhibitor therapy: a pilot study. Oncotarget, 2018, 9, 30268-30278.	1.8	49
64	99mTc-besilesomab (ScintimunÂ®) in peripheral osteomyelitis: comparison with 99mTc-labelled white blood cells. European Journal of Nuclear Medicine and Molecular Imaging, 2011, 38, 899-910.	6.4	48
65	Imaging of Î²-Cell Mass and Insulitis in Insulin-Dependent (Type 1) Diabetes Mellitus. Endocrine Reviews, 2012, 33, 892-919.	20.1	48
66	PET Radiopharmaceuticals for Specific Bacteria Imaging: A Systematic Review. Journal of Clinical Medicine, 2019, 8, 197.	2.4	48
67	Somatostatin receptor scintigraphy using 99mTc-EDDA/HYNIC-TOC in patients with medullary thyroid carcinoma. European Journal of Nuclear Medicine and Molecular Imaging, 2007, 34, 1635-1645.	6.4	45
68	Troglitazone prevents insulin dependent diabetes in the non-obese diabetic mouse. European Journal of Pharmacology, 1998, 357, 221-225.	3.5	44
69	99mTc-interleukin-2 and 99mTc-HMPAO granulocyte scintigraphy in patients with inactive Crohn's disease. European Journal of Nuclear Medicine and Molecular Imaging, 2003, 30, 374-382.	6.4	44
70	The need of standardization and of large clinical studies in an emerging indication of [18F]FDG PET: the autoimmune encephalitis. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 353-357.	6.4	44
71	Patient Age Is an Independent Risk Factor of Relapse of Differentiated Thyroid Carcinoma and Improves the Performance of the American Thyroid Association Stratification System. Thyroid, 2020, 30, 713-719.	4.5	43
72	123I-Interleukin-2: biochemical characterization and in vivo use for imaging autoimmune diseases. Nuclear Medicine Communications, 2003, 24, 305-316.	1.1	41

#	Article	IF	Citations
73	In vivo biodistribution of stem cells using molecular nuclear medicine imaging. Journal of Cellular Physiology, 2011, 226, 1444-1452.	4.1	41
74	In vivo and in vitro evidence that 99mTc-HYNIC-interleukin-2 is able to detect T lymphocytes in vulnerable atherosclerotic plaques of the carotid artery. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 1710-1719.	6.4	41
75	A multi-centre randomized trial of two different doses of nicotinamide in patients with recent-onset Type 1 diabetes (the IMDIAB VI). Diabetes/Metabolism Research and Reviews, 1999, 15, 181-185.	4.0	40
76	Raised temperature reduces the incidence of diabetes in the NOD mouse. Diabetologia, 1990, 33, 635-637.	6.3	38
77	Histological study of pancreatic beta-cell loss in relation to the insulitis process in the non-obese diabetic mouse. Histochemistry, 1994, 101, 263-269.	1.9	37
78	In Vivo Imaging of Natural Killer Cell Trafficking in Tumors. Journal of Nuclear Medicine, 2015, 56, 1575-1580.	5.0	37
79	Diagnosis of peripheral bone and prosthetic joint infections: overview on the consensus documents by the EANM, EBJIS, and ESR (with ESCMID endorsement). European Radiology, 2019, 29, 6425-6438.	4.5	36
80	Molecular imaging in atherosclerosis. European Journal of Nuclear Medicine and Molecular Imaging, 2010, 37, 2381-2397.	6.4	35
81	Detection of Insulitis by Pancreatic Scintigraphy With 99mTc-Labeled IL-2 and MRI in Patients With LADA (Action LADA 10). Diabetes Care, 2015, 38, 652-658.	8.6	35
82	MRI in the evaluation of facial dermal fillers in normal and complicated cases. European Radiology, 2015, 25, 1431-1442.	4.5	35
83	99mTc-interleukin-2 scintigraphy as a potential tool for evaluating tumor-infiltrating lymphocytes in melanoma lesions: a validation study. Journal of Nuclear Medicine, 2004, 45, 1647-52.	5.0	35
84	Randomized Trial Comparing Nicotinamide and Nicotinamide Plus Cyclosporin in Recent Onset Insulinâ€dependent Diabetes (IMDIAB 1). Diabetic Medicine, 1994, 11, 98-104.	2.3	34
85	CTLA-4 and HLA gene susceptibility to thyroidassociated orbitopathy. Lancet, The, 1999, 354, 1824.	13.7	33
86	Synthesis and Optimization of the Labeling Procedure of 99mTc-Hynic-Interleukin-2 for In vivo Imaging of Activated T lymphocytes. Molecular Imaging and Biology, 2010, 12, 539-546.	2.6	33
87	About inflammation and infection. EJNMMI Research, 2013, 3, 8.	2.5	33
88	Somatostatin receptor imaging by SPECT and PET in patients with chronic inflammatory disorders: a systematic review. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 2496-2513.	6.4	33
89	Thyroid Cancer Imaging In Vivo by Targeting the Anti-Apoptotic Molecule Galectin-3. PLoS ONE, 2008, 3, e3768.	2.5	33
90	Class-II and IL 2 receptor positive cells in the pancreas of NOD mice. Diabetologia, 1987, 30, 902-905.	6.3	33

#	Article	IF	Citations
91	Can we produce an image of bacteria with radiopharmaceuticals?. European Journal of Nuclear Medicine and Molecular Imaging, 2008, 35, 1051-1055.	6.4	32
92	Intra-articular infliximab in patients with rheumatoid arthritis and psoriatic arthritis with monoarthritis resistant to local glucocorticoids. Clinical efficacy extended to patients on systemic anti-tumour necrosis factor Â. Annals of the Rheumatic Diseases, 2008, 67, 1787-1790.	0.9	32
93	New approach for in vivo detection of insulitis in type I diabetes: activated lymphocyte targeting with 123I-labelled interleukin 2. European Journal of Endocrinology, 1994, 131, 431-437.	3.7	31
94	THE DEVELOPING ROLE OF CYTOKINES FOR IMAGING INFLAMMATION AND INFECTION. Cytokine, 2000, 12, 1445-1454.	3.2	31
95	Pharmacokinetic modelling of N-(4-[18F]fluorobenzoyl)interleukin-2 binding to activated lymphocytes in an xenograft model of inflammation. European Journal of Nuclear Medicine and Molecular Imaging, 2012, 39, 1551-1560.	6.4	31
96	Nuclear Medicine Imaging in Pediatric Infection or Chronic Inflammatory Diseases. Seminars in Nuclear Medicine, 2017, 47, 286-303.	4.6	31
97	18-fluorodeoxyglucose positron emission tomography in nonendocrine neoplastic disorders of the gastrointestinal tract. Gastroenterology, 2003, 125, 1235-1245.	1.3	30
98	Role of scintigraphy with 99mTc-infliximab in predicting the response of intraarticular infliximab treatment in patients with refractory monoarthritis. European Journal of Nuclear Medicine and Molecular Imaging, 2012, 39, 1339-1347.	6.4	30
99	Current Status of Molecular Imaging in Infections. Current Pharmaceutical Design, 2018, 24, 754-771.	1.9	29
100	Current Status of Molecular Imaging in Inflammatory and Autoimmune Disorders. Current Pharmaceutical Design, 2018, 24, 743-753.	1.9	29
101	Hybrid imaging of musculoskeletal infections. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2018, 62, 3-13.	0.7	28
102	Multidisciplinary Management of Neuroendocrine Neoplasia: A Real-World Experience from a Referral Center. Journal of Clinical Medicine, 2019, 8, 910.	2.4	28
103	Tumour angiogenesis pathways: related clinical issues and implications for nuclear medicine imaging. European Journal of Nuclear Medicine and Molecular Imaging, 2002, 29, 699-709.	6.4	27
104	Synthesis of 99mTc-HYNIC-interleukin-12, a new specific radiopharmaceutical for imaging T lymphocytes. European Journal of Nuclear Medicine and Molecular Imaging, 2006, 33, 474-482.	6.4	27
105	Pancreatic scintigraphy with 99mTc-interleukin-2 at diagnosis of type 1 diabetes and after 1 year of nicotinamide therapy. Diabetes/Metabolism Research and Reviews, 2008, 24, 115-122.	4.0	27
106	Prognostic Value of CD25 Expression on Lymphocytes and Tumor Cells in Squamous-Cell Carcinoma of the Head and Neck. Cancer Biotherapy and Radiopharmaceuticals, 2008, 23, 25-33.	1.0	27
107	Involvement of pro-inflammatory cytokines and growth factors in the pathogenesis of Dupuytren's contracture: a novel target for a possible future therapeutic strategy?. Clinical Science, 2015, 129, 711-720.	4.3	27
108	¹¹C-Hydroxytryptophan Uptake and Metabolism in Endocrine and Exocrine Pancreas. Journal of Nuclear Medicine, 2012, 53, 1755-1763.	5.0	26

#	Article	IF	Citations
109	Differences in the location and activity of intestinal Crohnâ€™s disease lesions between adult and paediatric patients detected with MRI. European Radiology, 2012, 22, 2465-2477.	4.5	26
110	Radiolabelled white blood cell scintigraphy in the work-up of dermal filler complications. European Journal of Nuclear Medicine and Molecular Imaging, 2013, 40, 418-425.	6.4	26
111	Comparison of White Blood Cell Scintigraphy, FDG PET/CT and MRI in Suspected Diabetic Foot Infection: Results of a Large Retrospective Multicenter Study. Journal of Clinical Medicine, 2020, 9, 1645.	2.4	26
112	Imaging of cell trafficking in Crohn's disease. Journal of Cellular Physiology, 2010, 223, 562-571.	4.1	25
113	Biological Therapies for Rheumatoid Arthritis: Progress to Date. BioDrugs, 2013, 27, 329-345.	4.6	25
114	Diabetic Foot Infections: The Diagnostic Challenges. Journal of Clinical Medicine, 2020, 9, 1779.	2.4	25
115	99mTc-EDDA/HYNIC-TOC in the Management of Medullary Thyroid Carcinoma. Cancer Biotherapy and Radiopharmaceuticals, 2004, 19, 211-217.	1.0	24
116	High Plasma Levels of Human Chromogranin a and Adrenomedullin in Patients with Pheochromocytoma. Tumori, 2005, 91, 53-58.	1.1	24
117	Labelling of lymphocytes with indium 111 oxine: Effect on cell surface phenotype and antibody-dependent cellular cytotoxicity. Immunology Letters, 1983, 6, 151-154.	2.5	23
118	In vivo imaging of insulitis in autoimmune diabetes. Journal of Endocrinological Investigation, 1999, 22, 151-158.	3.3	23
119	Assessment of Cancer-Associated Biomarkers by Positron Emission Tomography: Advances and Challenges. Disease Markers, 2002, 18, 211-247.	1.3	23
120	Small animal imaging by single photon emission using pinhole and coded aperture collimation. IEEE Transactions on Nuclear Science, 2005, 52, 573-579.	2.0	23
121	Receptor Binding Ligands to Image Infection. Current Pharmaceutical Design, 2008, 14, 3316-3325.	1.9	23
122	Radiolabeled Humanized Anti-CD3 Monoclonal Antibody Visilizumab for Imaging Human T-Lymphocytes. Journal of Nuclear Medicine, 2009, 50, 1683-1691.	5.0	23
123	Use of a 99mTc labeled anti-TNFalpha monoclonal antibody in Crohn's disease: in vitro and in vivo studies. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2007, 51, 334-42.	0.7	23
124	Evidence-based guideline of the European Association of Nuclear Medicine (EANM) on imaging infection in vascular grafts. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 3430-3451.	6.4	23
125	CD95 and CD95-ligand expression in endocrine pancreas of NOD, NOR and BALB/c mice. Diabetologia, 1997, 40, 1476-1479.	6.3	22
126	Diagnosis of Vascular Prosthesis Infection: PET or SPECT?. Journal of Nuclear Medicine, 2007, 48, 1227-1229.	5.0	22

#	Article	IF	Citations
127	123I-Interleukin-2 uptake in squamous cell carcinoma of the head and neck carcinoma. European Journal of Nuclear Medicine and Molecular Imaging, 2008, 35, 281-286.	6.4	22
128	Somatostatin receptor scintigraphy in patients with rheumatoid arthritis and secondary SjÃ¶grenâ€™s syndrome treated with Infliximab: a pilot study. EJNMMI Research, 2016, 6, 49.	2.5	22
129	Pre-clinical evaluation of eight DOTA coupled gastrin-releasing peptide receptor (GRP-R) ligands for in vivo targeting of receptor-expressing tumors. EJNMMI Research, 2016, 6, 17.	2.5	22
130	Imaging Modalities for the Diagnosis of Vascular Graft Infections: A Consensus Paper amongst Different Specialists. Journal of Clinical Medicine, 2020, 9, 1510.	2.4	22
131	The need of shared diagnostic protocols. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2014, 58, 1.	0.7	22
132	123I-Interleukin-2 Scintigraphy: A New Approach to Assess Disease Activity in Autoimmunity. Journal of Pediatric Endocrinology and Metabolism, 1996, 9, 139-44.	0.9	21
133	^{99m}Tc-anti-TNF-Î± antibody for the imaging of disease activity in pulmonary sarcoidosis. European Respiratory Journal, 2016, 47, 1198-1207.	6.7	21
134	New SPECT and PET Radiopharmaceuticals for Imaging Inflammatory Diseases: A Narrative Review. Seminars in Nuclear Medicine, 2018, 48, 261-276.	4.6	21
135	Fas and Fas ligand-mediated apoptosis and its role in autoimmune diabetes. , 1998, 14, 197-206.		20
136	Prognostic relevance of pancreatic uptake of technetium-99m labelled human polyclonal immunoglobulins in patients with type 1 diabetes. European Journal of Nuclear Medicine and Molecular Imaging, 1998, 25, 503-508.	6.4	20
137	Inflammatory bowel diseases: clinical update of practical guidelines. Nuclear Medicine Communications, 2005, 26, 649-655.	1.1	20
138	New radiopharmaceuticals for imaging rheumatoid arthritis. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2006, 50, 217-25.	0.7	20
139	Biological evaluation of a polyvinyl siloxane impression material. Dental Materials, 2005, 21, 371-374.	3.5	19
140	99mTc-interleukin-2 scintigraphy in normal subjects and in patients with autoimmune thyroid diseases: a feasibility study. European Journal of Nuclear Medicine and Molecular Imaging, 2008, 35, 2286-2293.	6.4	19
141	Decontamination of Root Canals with the Gallium-Aluminum-Arsenide Laser: Anin VitroStudy. Photomedicine and Laser Surgery, 2008, 26, 367-370.	2.0	19
142	In-vivo imaging of tumor-infiltrating immune cells: implications for cancer immunotherapy. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2018, 62, 56-77.	0.7	19
143	Radiolabelled Probes Targeting Infection and Inflammation for Personalized Medicine. Current Pharmaceutical Design, 2014, 20, 2338-2345.	1.9	18
144	Leukocyte Imaging of the Diabetic Foot. Current Pharmaceutical Design, 2018, 24, 1270-1276.	1.9	18

#	Article	IF	Citations
145	Imaging T-lymphocytes in inflammatory diseases: a nuclear medicine approach. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2014, 58, 237-57.	0.7	18
146	Radiolabelled Peptides and Monoclonal Antibodies for Therapy Decision Making in Inflammatory Diseases. Current Pharmaceutical Design, 2008, 14, 2401-2414.	1.9	17
147	Imaging Infection and Inflammation. BioMed Research International, 2015, 2015, 1-3.	1.9	17
148	Value of Somatostatin Receptor Scintigraphy with 99mTc-HYNIC-TOC in Patients with Primary SjÃ¶gren Syndrome. Journal of Clinical Medicine, 2019, 8, 763.	2.4	17
149	Receptor-mediated tumor targeting with radiolabeled peptides: there is more to it than somatostatin analogs. Journal of Nuclear Medicine, 2006, 47, 1904-7.	5.0	17
150	Targeting T and B lymphocytes with radiolabelled antibodies for diagnostic and therapeutic applications. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2010, 54, 654-76.	0.7	17
151	FDG-PET in infectious and inflammatory disease. European Journal of Nuclear Medicine and Molecular Imaging, 2003, 30, 1571-1573.	6.4	16
152	Fever of unknown origin, infection of subcutaneous devices, brain abscesses and endocarditis. Nuclear Medicine Communications, 2006, 27, 213-222.	1.1	16
153	Prognostic value of FDG uptake by the bone marrow in squamous cell carcinoma of the head and neck. Nuclear Medicine Communications, 2008, 29, 431-435.	1.1	16
154	High Sensitive Thyroglobulin Assay on Thyroxine Therapy: Can it Avoid Stimulation Test in Low and High Risk Differentiated Thyroid Carcinoma Patients?. Hormone and Metabolic Research, 2013, 45, 664-668.	1.5	16
155	Labelling and Clinical Performance of Human Leukocytes Labelled with ^{99m}Tc-HMPAO Using LeukokitÂ® with Gelofusine versus LeukokitÂ® with HES as Sedimentation Agent. Contrast Media and Molecular Imaging, 2019, 2019, 1-8.	0.8	16
156	Immune cell labelling and tracking: implications for adoptive cell transfer therapies. EJNMMI Radiopharmacy and Chemistry, 2021, 6, 7.	3.9	16
157	Receptor targeting agents for imaging inflammation/infection: where are we now?. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2006, 50, 236-42.	0.7	16
158	Tolbutamide reduces the incidence of diabetes mellitus, but not insulitis, in the non-obese-diabetic mouse. Diabetologia, 1993, 36, 487-492.	6.3	15
159	ANNEXIN V DETECTION OF LIPOPOLYSACCHARIDE-INDUCED CARDIAC APOPTOSIS. Shock, 2007, 27, 69-74.	2.1	15
160	Synthesis and Evaluation of 99mTc-Labelled Monoclonal Antibody 1D09C3 for Molecular Imaging of Major Histocompatibility Complex Class II Protein Expression. Molecular Imaging and Biology, 2011, 13, 930-939.	2.6	15
161	Evaluation of a Novel Tc-99m Labelled Vitamin B12 Derivative for Targeting Escherichia coli and Staphylococcus aureus In Vitro and in an Experimental Foreign-Body Infection Model. Molecular Imaging and Biology, 2015, 17, 829-837.	2.6	15
162	VEGF in nuclear medicine: Clinical application in cancer and future perspectives (Review). International Journal of Oncology, 2016, 49, 437-447.	3.3	15

#	Article	IF	Citations
163	Radiolabelled nanoparticles for cancer diagnosis. Clinical and Translational Imaging, 2018, 6, 271-292.	2.1	15
164	Immuno-Imaging to Predict Treatment Response in Infection, Inflammation and Oncology. Journal of Clinical Medicine, 2019, 8, 681.	2.4	15
165	Combination of Nicotinamide and Steroid Versus Nicotinamide in Recent-Onset IDDM: The IMDIAB II Study. Diabetes Care, 1994, 17, 897-900.	8.6	14
166	Biological Imaging for the Diagnosis of Inflammatory Conditions. BioDrugs, 2002, 16, 241-259.	4.6	14
167	Targeting cytokine/chemokine receptors: a challenge for molecular nuclear medicine. European Journal of Nuclear Medicine and Molecular Imaging, 2003, 30, 149-156.	6.4	14
168	Radiolabelled lymphokines and growth factors for in vivo imaging of inflammation, infection and cancer. Trends in Immunology, 2003, 24, 395-402.	6.8	14
169	^{99m}Tc-Labeled-rhTSH Analogue (TR1401) for Imaging Poorly Differentiated Metastatic Thyroid Cancer. Thyroid, 2014, 24, 1297-1308.	4.5	14
170	Radiolabeled Annexin-V for Monitoring Treatment Response in Oncology. Cancer Biotherapy and Radiopharmaceuticals, 2004, 19, 189-194.	1.0	13
171	Pharmacokinetic properties of radiolabeled mutant Interleukin-2v: a PET imaging study. Oncotarget, 2018, 9, 7162-7174.	1.8	13
172	Hybrid imaging in Crohn's disease: from SPECT/CT to PET/MR and new image interpretation criteria. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2018, 62, 40-55.	0.7	13
173	Scientific production and impact of nuclear medicine in Europe: how do we publish?. European Journal of Nuclear Medicine and Molecular Imaging, 2004, 31, 882-886.	6.4	12
174	In vivo apoptosis detection with radioiodinated Annexin V in LoVo tumour-bearing mice following Tipifarnib (Zarnestra, R115777) farnesyltransferase inhibitor therapy. Nuclear Medicine and Biology, 2005, 32, 233-239.	0.6	12
175	In VivoEvaluation of TNF-Alpha in the Lungs of Patients Affected by Sarcoidosis. BioMed Research International, 2015, 2015, 1-7.	1.9	12
176	State of the Art of Natural Killer Cell Imaging: A Systematic Review. Cancers, 2019, 11, 967.	3.7	12
177	Theranostic Designed Near-Infrared Fluorescent Poly (Lactic-co-Glycolic Acid) Nanoparticles and Preliminary Studies with Functionalized VEGF-Nanoparticles. Journal of Clinical Medicine, 2020, 9, 1750.	2.4	12
178	Diagnostic performance of PET/MR in the evaluation of active inflammation in Crohn disease. American Journal of Nuclear Medicine and Molecular Imaging, 2018, 8, 62-69.	1.0	12
179	Radioiodinated Recombinant Human TSH: A Novel Radiopharmaceutical for Thyroid Cancer Metastases Detection. Cancer Biotherapy and Radiopharmaceuticals, 2004, 19, 57-63.	1.0	11
180	Investigation of 99mTc-labelling of recombinant human interleukin-2 via hydrazinonicotinamide. Nuclear Medicine and Biology, 2010, 37, 795-803.	0.6	11

#	Article	IF	Citations
181	Molecular Imaging of Inflammatory Arthritis and Related Disorders. Seminars in Nuclear Medicine, 2018, 48, 277-290.	4.6	11
182	A radiopharmaceutical for imaging areas of lymphocytic infiltration: 123I-interleukin-2. Labelling procedure and animal studies. Nuclear Medicine Communications, 1992, 13, 713-22.	1.1	11
183	Labelling of Interleukin-2 (IL-2) with 123-Iodine with Retention of Its Capacity to Bind to Activated Lymphocytes. Experimental and Clinical Endocrinology and Diabetes, 1987, 89, 301-306.	1.2	10
184	Reduced cumulative incidence of diabetes but not insulitis following administration of chimeric human IL-15-murine IgG2b in NOD mice. Diabetes/Metabolism Research and Reviews, 2003, 19, 464-468.	4.0	10
185	Hybrid fusion images in diagnostic and therapeutic procedures. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2018, 62, 1-2.	0.7	10
186	Radiopharmaceuticals for imaging chronic lymphocytic inflammation. Brazilian Archives of Biology and Technology, 2007, 50, 1-13.	0.5	10
187	Synthesis and Biodistribution of 99mTc-Labeled PLGA Nanoparticles by Microfluidic Technique. Pharmaceutics, 2021, 13, 1769.	4.5	10
188	Metformin Does Not Alter Diabetes Incidence in the NOD Mouse. Hormone and Metabolic Research, 1997, 29, 261-263.	1.5	9
189	Nuclear Medicine Imaging For Prediction or Early Assessment of Response to Chemotherapy in Patients Suffering From Breast Carcinoma. Breast Cancer Research and Treatment, 2002, 72, 279-286.	2.5	9
190	Comparison of 99mTc-UBI 29-41, 99mTc-ciprofloxacin, 99mTc-ciprofloxacin dithiocarbamate and 111In-biotin for targeting experimental Staphylococcus aureus and Escherichia coli foreign-body infections: an ex-vivo study. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2019, 63, 37-47.	0.7	9
191	Effect of unlabeled indium oxine and indium tropolone on the function of isolated human lymphocytes. Journal of Nuclear Medicine, 1985, 26, 612-5.	5.0	9
192	Radiobelled white blood cells or FDG for imaging on inflammation and infection?. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2009, 53, 23-5.	0.7	9
193	Lymphopenia in patients affected by SARS-CoV-2 infection is caused by margination of lymphocytes in large bowel: an [18F]FDG PET/CT study. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 3419-3429.	6.4	9
194	In vivo kinetics of 1231-labelled insulin. Nuclear Medicine Communications, 1987, 8, 779-786.	1.1	8
195	A simple method for the evaluation of receptor binding capacity of modified cytokines. Journal of Immunological Methods, 1993, 166, 177-182.	1.4	8
196	9. Interleukin-2 scintigraphy: An overview. Nuclear Medicine Communications, 1999, 20, 938.	1.1	8
197	Radiopharmaceuticals for Breast Cancer and Neuroendocrine Tumors: Two Examples of How Tissue Characterization May Influence the Choice of Therapy. Cancers, 2020, 12, 781.	3.7	8
198	Role of [18F]FDG PET/CT in the management of G1 gastro-entero-pancreatic neuroendocrine tumors. Endocrine, 2022, 76, 484-490.	2.3	8

#	Article	IF	Citations
199	Relevance of 99mTc-HYNIC-tir-octreotide scintigraphy in a patient affected by sarcoidosis with lung and joints involvement and secondary Sjogren's syndrome treated with infliximab: case report. European Review for Medical and Pharmacological Sciences, 2008, 12, 127-30.	0.7	8
200	Peptide Receptor Imaging. Treatments in Respiratory Medicine, 2002, 1, 177-183.	1.2	7
201	Isolation and ¹¹¹Inâ€“Oxine Labeling of Murine NK Cells for Assessment of Cell Trafficking in Orthotopic Lung Tumor Model. Molecular Pharmaceutics, 2016, 13, 1329-1338.	4.6	7
202	Radiolabeling of VEGF165 with 99mTc to evaluate VEGFR expression in tumor angiogenesis. International Journal of Oncology, 2017, 50, 2171-2179.	3.3	7
203	Lower Gastrointestinal Tract Applications of PET/Computed Tomography and PET/MR Imaging. Radiologic Clinics of North America, 2018, 56, 821-834.	1.8	7
204	99mTc-HYNIC-IL-2 scintigraphy to detect acute rejection in lung transplantation patients: a proof-of-concept study. EJNMMI Research, 2019, 9, 41.	2.5	7
205	Handling of Doubtful WBC Scintigraphies in Patients with Suspected Prosthetic Joint Infections. Journal of Clinical Medicine, 2020, 9, 4031.	2.4	7
206	Extensive Histopathological Characterization of Inflamed Bowel in the Dextran Sulfate Sodium Mouse Model with Emphasis on Clinically Relevant Biomarkers and Targets for Drug Development. International Journal of Molecular Sciences, 2021, 22, 2028.	4.1	7
207	An easy and practical guide for imaging infection/inflammation by [18F]FDG PET/CT. Clinical and Translational Imaging, 2021, 9, 283-297.	2.1	7
208	Radiolabelled cytokines for imaging chronic inflammation. Brazilian Archives of Biology and Technology, 2002, 45, 15-23.	0.5	7
209	Analysis of Short-Term and Stable DNA Damage in Patients with Differentiated Thyroid Cancer Treated with ¹³¹I in Hypothyroidism or with Recombinant Human Thyroid-Stimulating Hormone for Remnant Ablation. Journal of Nuclear Medicine, 2022, 63, 1515-1522.	5.0	7
210	In vivo labelling of activated T lymphocytes by i.v. injection of 123I-IL2 for detection of insulitis in type 1 diabetes. Progress in Clinical and Biological Research, 1990, 355, 229-38.	0.2	7
211	Development and testing of a new disposable sterile device for labelling white blood cells. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2012, 56, 400-8.	0.7	7
212	The effect of metformin on liver blood flow in vivo in normal subjects and patients with non insulin dependent diabetes. Diabetes Research and Clinical Practice, 1996, 33, 83-87.	2.8	6
213	Comment on: â€œDiagnosis of Periprosthetic Joint Infection: The Role of Nuclear Medicine May Be Overestimatedâ€•by Claudio Diaz-Ledezma, Courtney Lamberton, Paul Lichtstein and Javad Parvizi. Journal of Arthroplasty, 2016, 31, 551-552.	3.1	6
214	In Vitro and In Vivo Evaluation of 99mTc-Polymyxin B for Specific Targeting of Gram-Bacteria. Biomolecules, 2021, 11, 232.	4.0	6
215	Copper-64 labeled nanoparticles for positron emission tomography imaging: a review of the recent literature. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2020, 64, 346-355.	0.7	6
216	Iodine-123-interleukin-2 scintigraphy in metastatic hypernephroma: a pilot study. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2007, 51, 352-6.	0.7	6

#	Article	IF	Citations
217	An overview of the diagnostic and therapeutic use of monoclonal antibodies in medicine. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2010, 54, 574-81.	0.7	6
218	Usefulness of 68-Gallium PET in Type I Gastric Neuroendocrine Neoplasia: A Case Series. Journal of Clinical Medicine, 2022, 11, 1641.	2.4	6
219	Immunotherapy with Ciamexon in the Non Obese Diabetic (NOD) Mouse. Hormone and Metabolic Research, 1992, 24, 1-4.	1.5	5
220	What future for therapeutic prevention of Type I (insulin-dependent) diabetes mellitus?. Diabetologia, 1992, 35, 1093-1095.	6.3	5
221	False-Negative Tc-99m MIBI Scintigraphy in Histopathologically Proved Recurrent High-Grade Oligodendroglioma. Clinical Nuclear Medicine, 2003, 28, 299-301.	1.3	5
222	Molecular Imaging of Vulnerable Coronary Plaque with Radiolabeled Somatostatin Receptors (SSTR). Journal of Clinical Medicine, 2021, 10, 5515.	2.4	5
223	Uptake of oxidized LDL by human atherosclerotic plaque. Circulation, 1997, 96, 2093-4.	1.6	5
224	The developing role of peptide radiopharmaceuticals in the study of chronic inflammation: new techniques for novel therapeutic options. The Quarterly Journal of Nuclear Medicine: Official Publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), 2003, 47, 256-69.	0.5	5
225	Clinical remission in patients with IDDM and family history of NIDDM. Lancet, The, 1991, 337, 1165.	13.7	4
226	Effect of metformin on liver insulin metabolism and regional blood flow. Diabetes/metabolism Reviews, 1995, 11, S13-S21.	0.3	4
227	EDITORIAL. Nuclear Medicine Communications, 2002, 23, 819-826.	1.1	4
228	Time for radiobiology in the nuclear medicine community. European Journal of Nuclear Medicine and Molecular Imaging, 2011, 38, 1267-1269.	6.4	4
229	Comment on Aksoy et al.: FDG and FDG-labelled leucocyte PET/CT in the imaging of prosthetic joint infection. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 1811-1812.	6.4	4
230	Editorial: Molecular Imaging of Inflammation/Infection: The Future of Disease Management. Current Pharmaceutical Design, 2018, 24, 741-742.	1.9	4
231	The reconstructed natural history of type 1 diabetes mellitus. Nature Reviews Endocrinology, 2019, 15, 256-257.	9.6	4
232	Uptake pattern of [68Ga]Ga-DOTA-NOC in tissues: implications for inflammatory diseases. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2019, , .	0.7	4
233	In vivo measurement of immunoglobulin accumulation in the pancreas of recent onset type 1 diabetic patients. Clinical and Experimental Rheumatology, 1996, 14 Suppl 15, S41-5.	0.8	4
234	Current status of PET imaging of differentiated thyroid cancer with second generation radiopharmaceuticals. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2015, 59, 105-15.	0.7	4

#	Article	IF	Citations
235	New approaches to image thyroid cancer cells and microenvironment. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2015, 59, 184-96.	0.7	4
236	Standardizing Experiments with NOD Mice. Autoimmunity, 1996, 24, 127-129.	2.6	3
237	Editorial. Nuclear Medicine Communications, 2001, 22, 945-947.	1.1	3
238	The Role of Positron Emission Tomography in Inflammatory Bowel Disease. European Journal of Inflammation, 2012, 10, 251-256.	0.5	3
239	In vivo imaging of microorganisms. Clinical and Translational Imaging, 2016, 4, 161-162.	2.1	3
240	Study of Binding Kinetics and Specificity of 99mTc-SSS-Complex and 99mTc-HMPAO to Blood Cells. Contrast Media and Molecular Imaging, 2018, 2018, 1-6.	0.8	3
241	In Vivo Imaging of Thyroid Cancer with 99mTc-TR1401 and 99mTc-TR1402: A Comparison Study in Dogs. Journal of Clinical Medicine, 2021, 10, 1878.	2.4	3
242	Detrimental effect of indium-111 on human lymphocytes. Journal of Nuclear Medicine, 1984, 25, 830.	5.0	3
243	SPECT imaging with 111In-octreotide for the localization of pancreatic insulinoma. The Quarterly Journal of Nuclear Medicine: Official Publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), 1995, 39, 111-2.	0.5	3
244	Diagnosis and followup of Takayasu's arteritis by scintigraphy with radiolabelled interleukin 2. Journal of Rheumatology, 2004, 31, 1225-7.	2.0	3
245	An in vitro study to compare 99mTc-stannous colloids and 99mTc-HMPAO for labelling human leukocytes. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2004, 48, 229-36.	0.7	3
246	The effect of a heparin analogue, ITF-5005, on diabetes incidence and insulitis in the non-obese diabetic mouse. Diabetes Research and Clinical Practice, 1993, 21, 5-9.	2.8	2
247	Nuclear Medicine Imaging of Abdominal Infections and Inflammation. , 2013, , 229-252.		2
248	Infection and inflammation imaging. Nuclear Medicine and Biology, 2014, 41, 488.	0.6	2
249	[18F]FDG-PET/CT and long-term responses to everolimus in advanced neuroendocrine neoplasia. Journal of Endocrinological Investigation, 2021, 44, 811-818.	3.3	2
250	Radionuclide Imaging of Infection and Inflammation. , 2013, , .		2
251	Imaging of autoimmune diseases. The Quarterly Journal of Nuclear Medicine: Official Publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), 1999, 43, 100-12.	0.5	2
252	Monoclonal antibodies for diagnosis and therapy decision making in inflammation/infection. Foreword. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2010, 54, 571-3.	0.7	2

#	Article	IF	Citations
253	4.P.288 The metabolic basis of a new form of recessive hypercholesterolemia: The â€œFH-likeâ€• hypercholesterolemia. Atherosclerosis, 1997, 134, 356-357.	0.8	1
254	Reply to comment by Koranda: 99mTc-HMPAO-labelled leucocytes in musculoskeletal infectionsâ€"the choice of reference tissue for a semiquantitative analysis. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 1030-1032.	6.4	1
255	RE: ^{99m}Tcâ€HMPAOâ€leucocyte scintigraphy and [¹⁸F]FDGâ€PET/CT in infection. Clinical Otolaryngology, 2020, 45, 652-653.	1.2	1
256	Nuclear Medicine Imaging of Abdominal Infections and Inflammations. , 2021, , 235-251.		1
257	The Contribution Of Nuclear Medicine In The Diagnosis Of Bone Metastases. Cancer Metastasis - Biology and Treatment, 2009, , 137-162.	0.1	1
258	Nuclear Medicine Imaging of Infections and Inflammation of Central Nervous System, Head and Neck Structures. , 2013, , 165-180.		1
259	Non-invasive clinical visualization of tumor infiltrating lymphocytes in patients with metastatic melanoma undergoing immune checkpoint inhibitor therapy: A pilot study.. Journal of Clinical Oncology, 2017, 35, 3034-3034.	1.6	1
260	Nuclear Medicine Imaging Modalities: Bone Scintigraphy, PET-CT, SPECT-CT. Cancer Metastasis - Biology and Treatment, 2014, , 71-94.	0.1	1
261	Applications of Molecular Small-Animal Imaging in Inflammation and Infection. , 2014, , 637-683.		1
262	Nuclear Medicine Imaging of Prosthetic Joint Infections. , 2020, , 119-132.		1
263	Gamma camera imaging of benign thyroid diseases. , 2022, , 45-58.		1
264	Homing and circulation of indium-111-labelled leucocytes. A post-mortem study. Diagnostic Imaging in Clinical Medicine, 1985, 54, 315-7.	0.1	1
265	Radiolabeling of monocytes, NK cells and dendritic cells and quality controls. , 2022, , 299-304.		1
266	Therapy of NET with radiolabeled SST analogs. , 2022, , .		1
267	CD95 ligand expression on alpha cells: protection or killing?. , 1998, 14, 191-192.		0
268	Novel PET and SPECT radioligands for visualization of diseased regulatory pathways in breast carcinoma. Nuclear Instruments and Methods in Physics Research, Section A: Accelerators, Spectrometers, Detectors and Associated Equipment, 2003, 497, 30-38.	1.6	0
269	Studying the Metabolic Activity of Red Bone Marrow by Means of FDG-PET: The Need for a Standardization. Molecular Imaging and Biology, 2008, 10, 129-130.	2.6	0
270	Infection Imaging Using SPECT-CT. , 2011, , 167-185.		0

#	Article	IF	Citations
271	The Role of Nuclear Medicine in Inflammatory Diseases: Drug Targets and Clinical Applications. , 2012, , 629-679.		0
272	Infection and inflammation imaging standardization: the EANM guidelines. Clinical and Translational Imaging, 2018, 6, 253-255.	2.1	0
273	Letter to the Editor regarding Falstie-Jensen etÂal: â€œLabeled white blood cell/bone marrow single-photon emission computed tomography with computed tomography fails in diagnosing chronic periprosthetic shoulder joint infectionâ€• Journal of Shoulder and Elbow Surgery, 2019, 28, e250-e251.	2.6	0
274	Reply to comment by J.P. Suarez Fernandez on â€œConsensus document for the diagnosis of prosthetic joint infections: a joint paper by the EANM, EBJIS, and ESR (with ESCMID endorsement)â€• European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 2503-2504.	6.4	0
275	Nuclear Medicine Imaging of Infections and Inflammation of Central Nervous System and of the Head and Neck Structures. , 2021, , 167-181.		0
276	Molecular Imaging of Autoimmune Diseases. , 2021, , 1393-1414.		0
277	Recent Advancements in Hematology: Knowledge, Methods and Dissemination, Part 2. Hemato, 2021, 2, 79-88.	0.6	0
278	Discordant Findings Between Tc-99m HMPAO Mixed Leukocytes and Tc-99mâ€“Labeled Monoclonal Antibody Fragments (via LeukoScan) in a Patient with Pulmonary Aspergillosis. Clinical Nuclear Medicine, 2002, 27, 596.	1.3	0
279	Inflammatory Bowel Diseases: The Use of Radiolabelled Cytokines for In Vivo Evaluation of Inflammatory Activity. , 2003, , 25-30.		0
280	99mTc Labelling of Interleukin-2 for in Vivo Targeting of Activated T-Lymphocytes. , 1994, , 49-52.		0
281	In Vivo Detection of Lymphocytic Infiltration: Present Status and New Prospects. , 1994, , 267-271.		0
282	In Vivo Detection of Activated Lymphocytes in Immune- Mediated Diseases by 123I-Interleukin-2 Scintigraphy. , 1997, , 157-163.		0
283	Autoimmune diseases. , 1998, , 139-147.		0
284	PET/MRI in Inflammatory Diseases. , 2018, , 123-135.		0
285	Nuclear Medicine Imaging of Diabetic Foot Infections. , 2020, , 145-160.		0
286	Nuclear Medicine Imaging of Infection/Inflammation by PET/CT and PET/MR. , 2020, , 213-235.		0
287	Nuclear Medicine Imaging of Vascular Graft Infections. , 2020, , 133-144.		0
288	Acquisition Protocols and Image Interpretation Criteria Nuclear Medicine Imaging of Infectious Diseases. , 2020, , 61-71.		0

#	Article	IF	Citations
289	PET Imaging of Autoimmune Diseases and Inflammatory Bowel Diseases. , 2021, , .		0
290	Radiolabeling of mixed leukocytes or pure granulocytes and their quality controls. , 2022, , .		0
291	Receptor ligands. The Quarterly Journal of Nuclear Medicine: Official Publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), 1995, 39, 83-5.	0.5	0
292	Imaging of inflammatory reactions. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2014, 58, 235-6.	0.7	0
293	The long history of the International Research Group in Immuno-Scintigraphy and Therapy (IRIST). Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2015, 59, 137-9.	0.7	0
294	Gamma camera imaging of autoimmune diseases. , 2022, , .		0
295	PET imaging of bacteria. , 2022, , .		0
296	PET imaging in diabetic foot infections. , 2022, , .		0
297	Gamma-Camera Imaging of Vascular Graft Infections. , 2022, , .		0
298	Gamma camera imaging of bacteria. , 2022, , .		0
299	Gamma-camera imaging of diabetic foot infections. , 2022, , .		0
300	Gamma camera imaging of inflammatory bowel diseases. , 2022, , 494-502.		0